[1]
Lim SA, Ethambutol-associated optic neuropathy. Annals of the Academy of Medicine, Singapore. 2006 Apr; [PubMed PMID: 16710500]
[2]
Palomino JC,Martin A, Drug Resistance Mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel, Switzerland). 2014 Jul 2; [PubMed PMID: 27025748]
[3]
Schubert K,Sieger B,Meyer F,Giacomelli G,Böhm K,Rieblinger A,Lindenthal L,Sachs N,Wanner G,Bramkamp M, The Antituberculosis Drug Ethambutol Selectively Blocks Apical Growth in CMN Group Bacteria. mBio. 2017 Feb 7; [PubMed PMID: 28174310]
[4]
Zhu C,Liu Y,Hu L,Yang M,He ZG, Molecular mechanism of the synergistic activity of ethambutol and isoniazid against {i}Mycobacterium tuberculosis{/i}. The Journal of biological chemistry. 2018 Oct 26; [PubMed PMID: 30185616]
[5]
Donald PR,Maher D,Maritz JS,Qazi S, Ethambutol dosage for the treatment of children: literature review and recommendations. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2006 Dec; [PubMed PMID: 17167947]
[6]
Jeong I,Park JS,Cho YJ,Yoon HI,Song J,Lee CT,Lee JH, Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. Journal of Korean medical science. 2015 Feb; [PubMed PMID: 25653488]
[7]
Bouffard MA,Nathavitharana RR,Yassa DS,Torun N, Re-Treatment With Ethambutol After Toxic Optic Neuropathy. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2017 Mar; [PubMed PMID: 27636749]
[8]
Nemati E,Mokhtarzadeh A,Panahi-Azar V,Mohammadi A,Hamishehkar H,Mesgari-Abbasi M,Ezzati Nazhad Dolatabadi J,de la Guardia M, Ethambutol-Loaded Solid Lipid Nanoparticles as Dry Powder Inhalable Formulation for Tuberculosis Therapy. AAPS PharmSciTech. 2019 Feb 22; [PubMed PMID: 30796625]
[9]
Geyer HL,Herskovitz S,Slamovits TL,Schaumburg HH, Optochiasmatic and peripheral neuropathy due to ethambutol overtreatment. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2014 Sep; [PubMed PMID: 24897009]
[10]
Behera C,Krishna K,Singh HR, Antitubercular drug-induced violent suicide of a hospitalised patient. BMJ case reports. 2014 Jan 6; [PubMed PMID: 24395874]
[12]
Park JS,Lee JY,Lee YJ,Kim SJ,Cho YJ,Yoon HI,Lee CT,Song J,Lee JH, Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome. Antimicrobial agents and chemotherapy. 2016 Jan; [PubMed PMID: 26459901]
[13]
Lounis N,Maslo C,Truffot-Pernot C,Grosset J,Boelaert RJ, Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2003 Jun; [PubMed PMID: 12797701]
[14]
Kim KL,Park SP, Visual function test for early detection of ethambutol induced ocular toxicity at the subclinical level. Cutaneous and ocular toxicology. 2016 Sep; [PubMed PMID: 26361935]
[15]
Abbasi Nazari M,Kobarfard F,Tabarsi P,Salamzadeh J, Serum copper (cu) alterations in pulmonary tuberculosis patients under treatment with ethambutol. Biological trace element research. 2009 May; [PubMed PMID: 19002388]
[16]
Kozak SF,Inderlied CB,Hsu HY,Heller KB,Sadun AA, The role of copper on ethambutol's antimicrobial action and implications for ethambutol-induced optic neuropathy. Diagnostic microbiology and infectious disease. 1998 Feb; [PubMed PMID: 9554173]
[17]
Chamberlain PD,Sadaka A,Berry S,Lee AG, Ethambutol optic neuropathy. Current opinion in ophthalmology. 2017 Nov; [PubMed PMID: 28759559]
[18]
Valencia S,León M,Losada I,Sequera VG,Fernández Quevedo M,García-Basteiro AL, How do we measure adherence to anti-tuberculosis treatment? Expert review of anti-infective therapy. 2017 Feb; [PubMed PMID: 27910715]